Log in

NASDAQ:MLNTMelinta Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.35
MA: $0.48
$0.50
52-Week Range N/A
VolumeN/A
Average Volume713,628 shs
Market Capitalization$6.88 million
P/E RatioN/A
Dividend YieldN/A
Beta4.16
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.
Read More
Melinta Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.9Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MLNT
CUSIP15130J10
Phone908-617-1309

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$96.43 million
Book Value$16.96 per share

Profitability

Net Income$-157,190,000.00
Net Margins-393.39%

Miscellaneous

Employees290
Market Cap$6.88 million
Next Earnings DateN/A
OptionableOptionable

Receive MLNT News and Ratings via Email

Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter.

Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Melinta Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Melinta Therapeutics.

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics Inc (NASDAQ:MLNT) posted its earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to analyst estimates of $15.51 million. Melinta Therapeutics had a negative return on equity of 101.29% and a negative net margin of 393.39%. View Melinta Therapeutics' earnings history.

When did Melinta Therapeutics' stock split? How did Melinta Therapeutics' stock split work?

Melinta Therapeutics's stock reverse split before market open on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for MLNT?

5 Wall Street analysts have issued 1 year price targets for Melinta Therapeutics' stock. Their forecasts range from $13.00 to $15.00. On average, they anticipate Melinta Therapeutics' stock price to reach $14.00 in the next twelve months. View analysts' price targets for Melinta Therapeutics.

What are Wall Street analysts saying about Melinta Therapeutics stock?

Here are some recent quotes from research analysts about Melinta Therapeutics stock:
  • 1. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (1/15/2020)
  • 2. HC Wainwright analysts commented, "We note that after a brief spike to $4.98 late Tuesday morning, MLNT shares closed last night at $3.75 per share, down $0.43 (-10.3%) since the release, versus NBI essentially flat (-0.4%) over the same period. First, the expected net product sales figure of $13.8M in the quarter is a slight 3% increase from our recently-lowered prior estimate of $13.4M. for CABP by Adjust PT to $13. We have now adjusted our estimate to match guidance. However, with 1H19 net product sales at about $25.6M, net sales growth in 2H19 would need to be at least 49% over 1H19 to meet the full-year 2019 minimum product sales of $63.75M as required by the Deerfield debt facility. This degree of growth acceleration seems unlikely to us the sequential growth in 2Q19 was 17%." (7/18/2019)

Has Melinta Therapeutics been receiving favorable news coverage?

News stories about MLNT stock have trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Melinta Therapeutics earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutMelinta Therapeutics.

Who are some of Melinta Therapeutics' key competitors?

What other stocks do shareholders of Melinta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Advanced Micro Devices (AMD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Nabriva Therapeutics (NBRV), NVIDIA (NVDA) and Novavax (NVAX).

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the following people:
  • Dr. Erin M. Duffy, Chief Scientific Officer & Exec. VP (Age 51)
  • Mr. John H. Johnson, CEO & Director (Age 61)
  • Dr. Thomas A. Steitz, Co-Founder
  • Dr. Peter B. Moore Ph.D., Co-Founder
  • Dr. William L. Jorgensen, Co-Founder

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

How big of a company is Melinta Therapeutics?

Melinta Therapeutics has a market capitalization of $0.00 and generates $96.43 million in revenue each year. The biotechnology company earns $-157,190,000.00 in net income (profit) each year or ($17.72) on an earnings per share basis. Melinta Therapeutics employs 290 workers across the globe.

What is Melinta Therapeutics' official website?

The official website for Melinta Therapeutics is www.melinta.com.

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 44 WHIPPANY ROAD, MORRISTOWN NJ, 07960. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.